NutriLeads’ clinical trial demonstrates that daily intake of BeniCaros helps support protective innate immune responses

Pivotal study published in Nutrients showing that Nutrileads’ proprietary carrot-derived rhamnogalacturonan-I (cRG-I) (commercially known as BeniCaros) fiber, accelerates protective anti-viral immune responses and reduces symptoms after an experimental infection with common cold virus in humans.

20 January 2022, Wageningen, the Netherlands. Venture Challenge alumnus, NutriLeads, announced the publication of the positive results of a pivotal clinical trial demonstrating that its award-winning ingredient cRG-I, commercially known as Benicaros, helps support protective immune responses to a common respiratory infection.      

“The Dietary Intake of Carrot-Derived Rhamnogalacturonan-I Accelerates and Augments the Innate Immune and Anti-Viral Interferon Response to Rhinovirus Infection and Reduces Duration and Severity of Symptoms in Humans in a Randomized Trial” has been published in the open access journal Nutrients.

Conducted in collaboration with the Amsterdam University Medical Centre (UMC; location AMC), NIZO Food Research, and StatistiCal B.V. in the Netherlands, the BeniCaros clinical trial assessed how the food ingredient carrot-derived rhamnogalacturonan-I (cRG-I) impacted peoples’ responses to an experimentally induced mild rhinovirus infection. Rhinoviruses are responsible for common colds and impose an enormous economic burden on society. In the randomized, double-blind, placebo-controlled trial, 146 healthy adults were given either cRG-I or the placebo for eight weeks, after which they were exposed to a standardized dose of an attenuated rhinovirus via the nose. In the clinical study, daily consumption of BeniCaros prior to the rhinovirus infection significantly accelerated protective innate immune and antiviral responses, resulting in a 20% reduction in severity of symptoms, and a 25% reduction in symptom duration. 

source: Nutrileads